Caris expands its extensive network of leading cancer institutions committed to improving patient outcomes through innovations in precision medicine by welcoming Mass General Cancer Center. “We are thrilled to welcome Mass General Cancer Center, one of the world’s most respected centers, to the Caris Precision Oncology Alliance,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. “We’re eager to work with their researchers and investigators on our shared mission of improving outcomes of all patients affected by cancer through precision oncology research.” Learn more: https://lnkd.in/ggni-zgg
Caris Life Sciences’ Post
More Relevant Posts
-
Take a moment to read our great blog post!!!
Be sure to check out our latest blog post on Mary Crowley Cancer Research's attendance at the American Society of Clinical Oncology (ASCO)'s Annual Meeting! View abstracts, posters, presentations and more! https://lnkd.in/gN2ddidx
To view or add a comment, sign in
-
Our latest recommendations for NTRK fusion testing and management in lung cancer - Herbert Loong Peters Solange Alexander Drilon CUHK Medicine Erin Rudzinski #LungCancer #Cancer #OncoDaily #Oncology #NTRK #LCSM
Herbert Loong: Our latest recommendations for NTRK fusion testing and management in lung cancer - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Important factors to evaluate the quality of oncological care in LMICs - City Cancer Challenge https://lnkd.in/gTtCqgXP #oncodaily #oncology #cancer #research #CCan
Important factors to evaluate the quality of oncological care in LMICs - City Cancer Challenge - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Merck's anti-TIGIT quest. Can vibostolimab and pembrolizumab outshine pembrolizumab as a monotherapy? Hard to bet on TIGIT at the moment. The pursuit of anti-TIGIT therapies, as exemplified by the ongoing trial with vibostolimab, shows promise despite previous setbacks in cancer research. The potential efficacy of vibostolimab combined with pembrolizumab, particularly in endometrial cancer, could mark a significant breakthrough, validating the broader use of anti-TIGIT approaches in oncology. By aiming to exceed the success of pembrolizumab monotherapy, Merck's trial not only seeks to enhance the market potential of vibostolimab but also holds the promise of transformative advancements in cancer treatment. For exclusive coverage on Endometrial cancer at ASCO 2024 annual meeting, visit: https://lnkd.in/gw75iYYn #AntiTIGIT #Vibostolimab #Pembrolizumab #CancerResearch #Oncology #EndometrialCancer #Merck #ClinicalTrials #CancerBreakthrough #PharmaInnovation #CancerTreatment #Immunotherapy #MedicalResearch #PharmaNews #HealthcareAdvancements
Endometrial Cancer Preview ASCO 2024
delveinsight.com
To view or add a comment, sign in
-
TRIO has set the standard in cancer clinical trials execution. If you are a cancer clinical investigator, we invite you to join our global network of investigators and elevate oncology research together. You will get: · Access to TRIO trials: Receive early invitations to join new trials, ongoing updates about our cutting-edge research and invitations to specialized events · Global collaboration: Connect with peers conducting TRIO trials worldwide and have the opportunity to contribute to trials design. · Recognition and growth: Be recognized for your contributions. · Lead alongside Dr. Dennis Slamon, a pioneer in cancer treatment, and impact patient outcomes through groundbreaking trials. 🌐 Discover how your expertise can transform cancer care with TRIO. Let’s redefine the future of oncology together: https://lnkd.in/ge3WCF2P #OncologyInnovation
To view or add a comment, sign in
-
⭐️Today is #WorldCancerDay ! The global cancer incidence is on the rise, and the global cancer burden is expected to reach 28.4 million cases in 2040, a 47% rise from 2020. 👉🏼Globalizing precision oncology should be a major priority for cancer care in the upcoming decades. It is time to modify the precision oncology mantra: Give the right drug, to the right patient, at the right time in every country, to think globally and act locally. Read our commentary published in American Association for Cancer Research Journal Cancer Discovery Elizabeth McKenna 👉🏼Think Globally, Act Locally: Globalizing Precision Oncology OncoAlert Link: https://lnkd.in/eXXsjE-3
To view or add a comment, sign in
-
The next oncology patient navigation webinar is just a few days away! - American Society of Clinical Oncology (ASCO) American Cancer Society #ClinicalOncology #Cancer #NavigationServices #OncoDaily #Oncology #OncologyPatient
The next oncology patient navigation webinar is just a few days away! - ASCO - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
The April American Society of Clinical Oncology (ASCO) Plenary Series are here - Toni Choueiri https://lnkd.in/gwGsFvc3 #oncodaily #oncology #cancer #research #ASCO #ASCOPlenarySeries
Toni Choueiri: The April ASCO Plenary Series are here - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
Our editorial comments on the ASCO TAPUR study spearheaded by the amazing Richard Schilsky - Vivek Subbiah, MD American Society of Clinical Oncology (ASCO) #ASCO #Cancer #JCOPrecisionOncology #OncoDaily #Oncology #TAPURStudy
Vivek Subbiah: Our editorial comments on the ASCO TAPUR study spearheaded by the amazing Richard Schilsky - OncoDaily
oncodaily.com
To view or add a comment, sign in
-
This new review article is all about Tagraxofusp for BPDCN - ACS Journal Cancer Wei Ying Jen, Marina Konopleva, Naveen Pemmaraju, MD https://lnkd.in/gyAWR2Xx #oncodaily #oncology #cancer #hematologicalmalignancies #Tagraxofusp #BPDCN #AML #clinicalresearch #cancertherapy
This new review article is all about Tagraxofusp for BPDCN - ACS Journal Cancer - OncoDaily
oncodaily.com
To view or add a comment, sign in
57,673 followers